Pages on this site explain labelled tablet strengths for study. They are not a prescription, a pharmacy counter, or personal medical advice. Full disclaimer
Levitra 2.5 mg is contraindicated with certain QT-prolonging drugs
4 min readReviewed 21 August 2026. Updated
At a glance
Page typeNote
Featured strength2.5 mg
QT stopsClass IA / Class III / congenital
ReviewerCamille Rousseau, MD
LEVITRA is contraindicated in patients with congenital QT prolongation. LEVITRA is contraindicated with Class IA (e.g. quinidine, procainamide) or Class III (e.g. amiodarone, sotalol) antiarrhythmics.
01The labelled QT stops
LEVITRA is contraindicated in patients with congenital QT prolongation. LEVITRA is contraindicated with Class IA (e.g. quinidine, procainamide) or Class III (e.g. amiodarone, sotalol) antiarrhythmics.
The recommended starting dose of LEVITRA is 10 mg. LEVITRA is available as 2.5 mg, 5 mg, 10 mg, and 20 mg film-coated tablets.
The maximum recommended dosing frequency is once per day. Sexual stimulation is required. LEVITRA is not indicated for use in women.
02Organic nitrate stop
Vardenafil is contraindicated in patients using any form of organic nitrate, either regularly or intermittently. Administration of LEVITRA to patients who are using any form of organic nitrate is contraindicated.
Do not combine LEVITRA with other PDE5 inhibitors.
03How the 2.5 mg tablet is taken
LEVITRA is taken orally, as needed, approximately 60 minutes before sexual activity. The dose may be increased to a maximum recommended dose of 20 mg or decreased to 5 mg based on efficacy and side effects.
How to cite this page - Vancouver style
Halo Medix Medicines Reference. Levitra 2.5 mg is contraindicated with certain QT-prolonging drugs [Internet]. Montreal: Halo Medix; 21 August 2026 [cited 2026 Aug 21]. Available from: https://halomedix.com/notes/vardenafil-qt-screen/
('Readers around Montreal asked about the QT screen on 2.5 mg Levitra. ', 'Answers follow the U.S. Levitra label.')
Sophie Marchand, Westmount asks
Which heart-rhythm tablets sit on the Levitra stop list?
Reply from our reviewer
LEVITRA is contraindicated with Class IA (e.g. quinidine, procainamide) or Class III (e.g. amiodarone, sotalol) antiarrhythmics. LEVITRA is contraindicated in patients with congenital QT prolongation. The prescriber reads the full list. Vardenafil is also contraindicated in patients using any form of organic nitrate, either regularly or intermittently.
Éric Bouchard, Anjou asks
Is 2.5 mg the usual first Levitra tablet?
Reply from our reviewer
The recommended starting dose of LEVITRA is 10 mg. This note features 2.5 mg, the labelled lower start when that strength is written. LEVITRA is available as 2.5 mg, 5 mg, 10 mg, and 20 mg film-coated tablets. The dose may be increased to a maximum recommended dose of 20 mg or decreased to 5 mg based on efficacy and side effects. The maximum recommended dosing frequency is once per day.
Leila Rahman, Parc-Extension asks
Can I take Levitra if I already use nitroglycerin?
Reply from our reviewer
Administration of LEVITRA to patients who are using any form of organic nitrate is contraindicated. Vardenafil is contraindicated in patients using any form of organic nitrate, either regularly or intermittently. Do not combine LEVITRA with other PDE5 inhibitors. Sexual stimulation is required.
Guillaume Pelletier, Mercier asks
Is Levitra written for women with a long QT?
Reply from our reviewer
LEVITRA is not indicated for use in women. LEVITRA is contraindicated in patients with congenital QT prolongation. LEVITRA is taken orally, as needed, approximately 60 minutes before sexual activity.
Marc-Olivier Dion, Outremont asks
What tablet strengths are listed for LEVITRA?
Reply from our reviewer
LEVITRA is available as 2.5 mg, 5 mg, 10 mg, and 20 mg film-coated tablets. The recommended starting dose of LEVITRA is 10 mg. This note features 2.5 mg. The dose may be increased to a maximum recommended dose of 20 mg or decreased to 5 mg based on efficacy and side effects. The maximum recommended dosing frequency is once per day. LEVITRA is taken orally, as needed, approximately 60 minutes before sexual activity. Sexual stimulation is required.
Amina El-Hajj, Laval asks
Does food change the 2.5 mg swallow on this QT page?
Reply from our reviewer
LEVITRA may be taken with or without food. A high-fat meal may delay the time to peak concentration. LEVITRA is contraindicated in patients with congenital QT prolongation. LEVITRA is contraindicated with Class IA (e.g. quinidine, procainamide) or Class III (e.g. amiodarone, sotalol) antiarrhythmics.
Benoit Lacroix, Verdun asks
Is LEVITRA 2.5 mg written for pediatric patients?
Reply from our reviewer
LEVITRA is not indicated for use in women. Safety and effectiveness in pediatric patients have not been established on the U.S. Levitra label. The maximum recommended dosing frequency is once per day. Do not combine LEVITRA with other PDE5 inhibitors. 5 mg is a labelled lower tablet.
Chloé Haddad, LaSalle asks
Does the QT stop change the 60-minute swallow?
Reply from our reviewer
LEVITRA is taken orally, as needed, approximately 60 minutes before sexual activity. The QT stops do not rewrite that hour. LEVITRA is contraindicated in patients with congenital QT prolongation. LEVITRA is contraindicated with Class IA (e.g. quinidine, procainamide) or Class III (e.g. amiodarone, sotalol) antiarrhythmics. The maximum recommended dosing frequency is once per day. Sexual stimulation is required. LEVITRA may be taken with or without food. A high-fat meal may delay the time to peak concentration. The recommended starting dose of LEVITRA is 10 mg. This note features 2.5 mg.
Paul-Émile Roy, Lachine asks
Which reactions were reported at 2 percent or greater on Levitra?
Reply from our reviewer
Headache was reported in 15% of Levitra-treated patients and 4% on placebo in fixed and flexible-dose trials of 5 mg, 10 mg, or 20 mg. Flushing occurred in 11% versus 1%. Rhinitis occurred in 9% versus 3%. Dyspepsia occurred in 4% versus 1%. LEVITRA was administered to over 4430 men during controlled and uncontrolled clinical trials worldwide. In placebo-controlled clinical trials, the discontinuation rate due to adverse events was 3.4% for LEVITRA compared to 1.1% for placebo. This note features 2.5 mg. The maximum recommended dosing frequency is once per day.
